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homas R. Shannon, DVM, PHD,†
ilbur Y. W. Lew, MD‡
hicago, Illinois; and San Diego, California
alcium (Ca) handling by the myocyte in chronic heart
ailure is altered in a number of ways that lead to charac-
eristic dysfunction. The authors of numerous studies have
hown depressed cardiac calcium transients in isolated
yocytes, leading to decreased contractile function. Among
he most important reasons for this change are the de-
ressed sarcoplasmic reticulum (SR) Ca pump function
nd/or increased Na-Ca exchange activity, which are de-
ected in these cells (1,2). The combination of these effects
eads to a decrease in SR calcium concentration [Ca] and a
ubsequent decrease in SR Ca release, which depends upon
t in a steep, nonlinear fashion (3).
See page 1993
Given the decrease in Ca release that is observed during
ystole, one would expect that a decrease in diastolic release
i.e., SR Ca leak) through the ryanodine receptor (RyR)
ould also be observed in heart failure. However, in contrast
o this expectation, an increase in diastolic release of Ca has
een shown to take place in cardiac myocytes from heart
ailure hearts due to changes in the release process (4). Such
n increase could contribute to cellular dysfunction by
urther decreasing SR [Ca] and, at the same time, increasing
he probability of initiating triggered electrical activity.
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the †Department of Physiology and Molecular Biophysics, Rush University,a
hicago, Illinois; and the ‡Department of Medicine, Veterans Affairs San Diego
ealthcare System, University of California, San Diego, California.ossible Mechanisms by Which an SR Ca Leak
ay Be Increased in Heart Failure
here are a number of potential inter-related mechanisms that
ave been identified as being relevant to increasing the Ca leak
rom the SR, any or all of which may be involved in the
ncreased SR Ca leak that is found in patients with heart
ailure. One of the most prominent of these is modifications of
he RyR by phosphorylation. It has been shown that phos-
horylation of the RyR can take place in at least 3 sites (5–7)
nd that modulation of the RyR by either protein kinase A or
almodulin-dependent protein kinase may increase RyR open
robability (5,6,8). Indeed, increased SR Ca leak can be shown
o take place in intact myocytes in response to treatment with
soproterenol in a manner that is dependent upon Ca-
almodulin-dependent protein kinase activity (9).
A second possibility is increased SR Ca leak caused by
nhanced sensitivity to lumenal SR [Ca]. Kubalova et al.
10) showed that the sensitivity of the RyR to lumenal Ca at
he single-channel level was greatly enhanced in a dog
acing model of heart failure. Such a mechanism could
esult in sustained SR Ca leak at the lower SR [Ca], which
s characteristic of cells from hearts with chronic failure.
A third possibility is highlighted in the article by Koba-
ashi et al. (11) in this issue of the Journal. This proposed
echanism is based on a theory for increased diastolic Ca
elease proposed by Yamamoto et al. (12). According to this
ypothesis, interactions between the N-terminal and central
omains of the RyR stabilize the channel in the closed state.
eakening of these interactions either through channel
utation, as in malignant hyperthermia in skeletal muscle
nd catecholaminergic polymorphic ventricular tachycardia
n cardiac muscle (13), or via other mechanisms, would lead
o a destabilization of this state and an increase in open
robability at diastolic [Ca].
The authors have proposed that this mechanism is
elevant to heart failure (14). Specifically, they have shown
hat weakened interdomain interactions are associated with
issociation of the RyR regulatory protein, FKBP 12.6.
KBP 12.6 has been demonstrated to be dissociated to an
bnormally large degree in failure hearts, perhaps as the
esult of RyR phosphorylation by protein kinase A (8),
lthough the results are controversial (15).
Kobayashi et al. (11) provides further support for this
echanism by providing additional evidence that weakened
nterdomain interactions leading to increased SR Ca leak
re present in isolated membranes as well as in cardiomyo-
ytes from a dog pacing model of heart failure. The authors
urther show that dantrolene, a drug that is routinely used to
reat malignant hyperthermia, also stabilizes this interaction
n RyR2, the cardiac isoform of the release channel, thus
ecreasing the SR Ca leak.
athophysiological Significance of the SR Ca Leak
he results suggest that the interdomain interaction may be
therapeutic target for the treatment of heart disease. A
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May 26, 2009:2006–8 Diastolic Sarcoplasmic Reticulum Calcium Releaserug that reduces the SR Ca leak, perhaps by strengthening
his interaction, could prove to be a significant advance in
reatment of both related contractile dysfunction and trig-
ered arrhythmias.
Increased Ca-sensitivity of the RyR and increased dia-
tolic SR Ca release can lead to decreased SR Ca accumu-
ation (4), which can be attenuated by decreasing the SR Ca
eak. However, a perhaps more important effect of leak on
he cardiomyocyte may be its electrical behavior.
The directed leak of Ca toward the SR within the
unctional space may lead to Na-inward Na-Ca exchange
ctivity, thus depolarizing the sarcolemmal membrane (16).
he Na-Ca exchange up-regulation in heart failure would
ikely increase the degree to which this occurs. This, in
ombination with other changes, such as decreased inward
ectifier K current and transient outward current, may lead
o electrical instability (16,17) and the generation of delayed
fterdepolarizations.
In the whole heart, neighboring cells will act as current
inks, thus normally limiting the change in membrane
otential that may be produced by such a mechanism.
owever, a large cell cluster that depolarizes to a great
nough degree and in a synchronized manner could generate
fterdepolarizations, which lead to triggered arrhythmias in
he heart (18).
linical Translation of the Decreasing SR Ca Leak
his study should motivate clinical researchers to examine
he importance of SR Ca leak in human heart disease and
hether it can be modified to improve clinical outcomes.
gents have been developed to reduce SR Ca leak, such as
D201 (also known as JTV519, a 1-4-benzothiazepine
erivative), and beta-blockers, antioxidants, and carvedilol
ay reduce oxidative species to attenuate destabilization of
yR2 (19). The advance in this study is to identify a widely
vailable agent that specifically targets RyR2 interdomains
o reduce SR Ca leak, which could be a powerful tool.
Dantrolene has been used for decades to acutely treat
alignant hyperthermia and is used chronically to decrease
uscle spasticity associated with spinal cord injury, cerebral
alsy, multiple sclerosis, or after strokes (20–22). The
hronic administration of dantrolene is generally well toler-
ted and safe, although patients must be screened for
epatic toxicity.
The challenges in clinical translation require appropriate
atient selection and clinical end points, because in vivo
easurements of SR Ca leak are not feasible. Patients with
atecholaminergic polymorphic ventricular tachycardia may
enefit from this approach, because SR Ca leak may cause
elayed afterdepolarizations that predispose to arrhythmia,
nd mutations in RyR2 occur in approximately one-half of
he autosomal dominant cases (13,23,24). Patients with
atecholaminergic polymorphic ventricular tachycardia have
ormal resting electrocardiograms and no evidence of struc-
ural heart disease but do experience episodes of ventricularachycardia with exercise or stress that can lead to sudden
eath. Beta-adrenergic receptor blockers are useful, but 30%
f patients may still have ventricular events that require
mplantation of an intracardiac defibrillator. Dantrolene
ould be effective if its use raises the threshold before
entricular tachycardia develops with exercise or stress, or
educes the number of episodes.
This approach may be feasible for other RyR2 mutations
ssociated with sudden death, such as atypical right ventric-
lar cardiomyopathy. If dantrolene is effective only in
atients with RyR2 mutations at the specific dantrolene
inding site, this finding may limit its utility because many
f the mutations occur at other sites, or there are no
utations. If dantrolene is broadly effective, it could still be
linically useful but would require a refinement in the
ostulated mechanism of action.
Heart failure has been associated with SR Ca leak but is
ikely only one of multiple contributory factors. In that
egard, reducing SR Ca leak may provide significant addi-
ive benefits when used in combination with conventional
herapies. Dantrolene ex vivo improved myocardial function
n tissue isolated from patients with heart failure (25). If
antrolene in vivo has similar benefits in patients with
stablished heart failure, it might be reflected by improve-
ents in diastolic indexes, systolic function, and/or biomar-
ers. This could be a useful adjunct for the management of
cute decompensated heart failure. It may be more chal-
enging to document effects with chronic dantrolene, and
ould require demonstrating that the benefits are sustained
ithout adverse consequences (cf., that which occurred with
rolonged inotropic stimulation).
onclusions
he availability of a safe drug that targets stabilizing RyR2
o diminish SR Ca leak should motivate clinical studies to
etermine if this benefit can be translated to human heart
isease.
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